Anti-leukemic effects of gallic acid on human leukemia K562 cells: Downregulation of COX-2, inhibition of BCR/ABL kinase and NF-κB inactivation

Toxicology in Vitro

Volumn 26, Issue 3, 2012, Pages 396-405

  Chandramohan Reddy, T ^a   Bharat Reddy, D ^b   Aparna, A ^a   Arunasree, Kalle M ^a   Gupta, Geetika ^a   Achari, Chandrani ^a   Reddy, G V ^a   Lakshmipathi, V ^a   Subramanyam, A ^c   Reddanna, P ^a  

^a UNIVERSITY OF HYDERABAD   (India)

^b UNIVERSITY OF LOUISVILLE   (United States)

^c Dr A P J Abdul Kalam Technical University   (India)

Author keywords

BCR ABL kinase; Chronic myeloid leukemia (K562) cell line; Cyclooxygenase 2; Gallic acid; Imatinib resistant K562 cells; Nf B

Indexed keywords

BCR ABL PROTEIN; CASPASE 3; CASPASE 8; CYCLIN D; CYCLIN E; CYCLOOXYGENASE 2; CYTOCHROME C; DEATH RECEPTOR; FATTY ACID SYNTHASE; GALLIC ACID; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN P21; PROTEIN P27;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOSIS INHIBITION; PROTEIN CLEAVAGE; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CYCLOOXYGENASE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; GALLIC ACID; HUMANS; INHIBITORY CONCENTRATION 50; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MITOCHONDRIA; NF-KAPPA B; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 84857692045     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2011.12.018     Document Type: Article

References (53)

1. Agarwal C., Tyagi A., Agarwal R. Gallic acid causes inactivating phosphorylation of cdc25A/cdc25C-cdc2 via ATMChk2 activation, leading to cell cycle arrest, and induces apoptosis in human prostate carcinoma DU145 cells. Mol. Cancer Ther. 2006, 5:3294-3302.
2. Arunasree M.K., Roy K.R., Anilkumar K., Aparna A., Reddy G.V., Reddanna P. Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1. Leukemia Res. 2008, 32:855-864.
3. Bharat Reddy D., Reddy T.C., Jyotsna G., Sharan Satish., Priya Nalini., Lakshmipathi V., Reddanna P. Chebulagic acid, a COX-LOX dual inhibitor isolated from the fruits of Terminalia chebula Retz., induces apoptosis in COLO-205 cell line. J. Ethnopharmacol. 2009, 124:506-512.
4. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
5. Cárcamo J.M., Pedraza A., Bórquez-Ojeda O., Zhang B., Sanchez R., Golde D.W. Vitamin C is a kinase inhibitor: dehydroascorbic acid inhibits I-κBα kinase β. Mol. Cell Biol. 2004, 24(15):6645-6652.
6. Chandra J., Niemer I., Gilbreath J., Kliche K.O., Andreeff M., Freireich E.J., Keating M., McConkey D.J. Proteasome inhibitors induce apoptosis in glucocorticoid resistant chronic lymphocytic leukemic lymphocytes. Blood 1998, 92:4220-4229.
7. Chen, G., Wang, F., Trachootham, D., Huang, P., 2010. Preferential killing of cancer cells with mitochondrial dysfunction by natural compounds. Mitochondrion (doi:10.1016/j.mito.2010.08.001).
8. Chou T.C., Talalay P. Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol. Sci. 1983, 4:450-454.
9. Chou T.C., Tan Q.H., Sirotnak F.M. Quantification of the synergistic interaction of edatrexate and cisplatin in vitro. Cancer Chemoth. Pharm. 1993, 31:259-264.
10. Cory S., Adams J.M. The Bcl-2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2002, 2:647-656.
11. de Groot D.J., de Vries E.G., Groen H.J., de Jong S. Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: from lab to clinic. Crit. Rev. Oncol. Hemat. 2007, 61:52-69.
12. Evans J.F., Kargman S.L. Cancer and cyclooxygenase-2 (COX-2) inhibition. Curr. Pharm. Design 2004, 10:627-634.
13. Giftson J.S., Jayanthi S., Nalini N. Chemopreventive efficacy of gallic acid, an antioxidant and anticarcinogenic polyphenol, against 1, 2-dimethyl hydrazine induced rat colon carcinogenesis. Invest. New Drug. 2010, 28:251-259.
14. Giles F.J., Kantarjian H.M., Bekele B.N., Cortes J.E., Faderl S., Thomas D.A., Manshouri T.R., ogers A., Keating M.J., Talpaz M., O'Brien S., Albitar M. Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukemia and are associated with reduced survival. Br. J. Haematol. 2002, 119:38-45.
15. Goldman J.M., Melo J.V. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl. J. Med. 2003, 349:1451-1464.
16. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., Sawyers C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876-880.
17. Hanif R., Pittas A., Feng Y., Koutsos M.I., Qiao L., Staiano-Coico L., Shiff S.I., Rigas B. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem. Pharmacol. 1996, 52:237-245.
18. Hermann M., Lorenz H.M., Voll R., Grunke M., Woith W., Kalden J.R. A rapid and simple method for the isolation of apoptotic DNA fragments. Nucleic Acids Res. 1994, 22:5506-5507.
19. Hoover R.R., Mahon F.X., Melo J.V., et al. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood 2002, 100:1068-1071.
20. Hou A.J., Peng L.Y., Liu Y.Z., Lin Z.W., Sun H.D. Gallotannins and related polyphenols from Pistacia weinmannifolia. Planta Med. 2000, 66(7):624-626.
21. Inoue M., Suzuki R., Sakaguchi N., Li Z., Takeda T., Ogihara Y., Jiang B.Y., Chen Y. Selective induction of cell death in cancer cells by gallic acid. Biol. Pharm. Bull. 1995, 18:1526-1530.
22. Jendrossek V., Handrick R., Belka C. Celecoxib activates a novel mitochondrial apoptosis signaling pathway. FASEB J 2003, 17:1547-1549.
23. 4-induced acute liver injury in rats. Am. J. Chin. Med. 1998, 26:333-341.
24. Kaur M., Velmurugan B., Rajamanickam S., Agarwal R., Agarwal C. Gallic acid, an active constituent of grape seed extract, exhibits anti-proliferative, pro-apoptotic and anti-tumorigenic effects against prostate carcinoma xenograft growth in nude mice. Pharmaceut. Res. 2009, 26(9):2133-2140.
25. Khan Z., Khan N., Tiwari R.P., Sah N.K., Prasad G.B., Bisen P.S. Biology of Cox-2: an application in cancer therapeutics. Curr. Drug Targets 2011, 12(7):1082-1093.
26. La Rosee P., Johnson K., Corbin A.S., et al. In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib resistant Bcr-Abl positive cell lines. Blood 2004, 103:208-215.
27. Lazebnik Y.A., Kaufmann S.H., Desnoyers S., Poirier G.G., Earnshaw W.C. Cleavage of poly (ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 1994, 371:346-347.
28. Li M., Wu X., Xu X.C. Induction of apoptosis by cyclo-oxygenase-2 inhibitor NS398 through a cytochrome C-dependent pathway in esophageal cancer cells. Int. J. Cancer 2001, 93:218-223.
29. Liu K.Z., Schultz C.P., Johnston J.B., Lee K., Mantsch H.H. Comparison of infrared spectra of CLL cells with their ex vivo sensitivity (MTT assay) to chlorambucil and cladribine. Leukemia Res. 1997, 21:1125-1133.
30. Madlener S., Illmer C., Horvath Z., Saiko P., Losert A., Herbacek I., Grusch M., Elford H.L., Krupitza G., Bernhaus A., Szekeres M.F., Szekeres T. Gallic acid inhibits ribonucleotide reductase and cyclooxygenases in human HL-60 promyelocytic leukemia cells. Cancer Lett. 2007, 245:156-162.
31. Milella M., Gelibter A., Di Cosimo S., Bria E., Ruggeri E.M., Carlini P., Malaguti P., Pellicciotta M., Terzoli E., Cognetti F. Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer 2004, 101:133-138.
32. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65:55-63.
33. Mou H., Zheng Y., Zhao P., Bao H., Fang W., Xu N. Celastrol induces apoptosis in non-small-cell lung cancer A549 cells through activation of mitochondria- and Fas/FasL-mediated pathways. Toxicol In Vitro 2011, 25:1027-1032.
34. Nicholson W., Thornberry N.A. Caspases: killer proteases. Trends Biochem. Sci. 1997, 22:299-306.
35. Nicoletti I., Migliorati G., Pagliacci M.C., Grignani F., Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods 1991, 139:271-279.
36. Notarbartolo M., Poma P., Perri D., Dusonchet L., Cervello M., D'Alessandro N. Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells analysis of their possible relationship to changes in NF-k{cyrillic}B activation levels and in IAP gene expression. Cancer Lett. 2005, 224:53-65.
37. Pullen G.R., Chalmers P.J., Nind A.P., Nairn R.C. Criteria of cell killing in vitro. J. Immunol. Methods 1981, 43:87-93.
38. Reddy M.C., Subhashini J., Mahipal S.V.K., Bhat V.B., Reddy P.S., Kiranmai G., Madyastha K.M., Reddanna P. C-Phycocyanin, a selective cyclooxygenase-2 inhibitor, induces apoptosis in lipopolysaccharide-stimulated RAW 264.7 macrophages. Biochem. Biophys. Res. Co. 2003, 304:385-392.
39. Reddy T.C., Aparoy P., Kishore Babu N., Anil Kumar K., Kumar Kalangi S., Reddanna P. Kinetics and docking studies of a COX-2 inhibitor isolated from Terminalia bellerica fruits. Protein Peptide Lett. 2010, 17(10):1251-1257.
40. Rizzo M.T. Cyclooxygenase-2 in oncogenesis. Clin. Chim. Acta. 2011, 412(9-10):671-687.
41. Sakagami H., Yokote Y., Akahane K. Changes in amino acid pool and utilization during apoptosis in HL-60 cells induced by epigallocatechin gallate or gallic acid. Anticancer Res. 2001, 21:2441-2447.
42. Savage D.G., Antman K.H. Imatinib mesylate-a new oral targeted therapy. N Engl. J. Med. 2002, 346:683-693.
43. Shishodia S., Aggarwal B.B. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor-κB by suppressing activation of I-κBα kinase in human non-small cell lung carcinoma correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9. Cancer Res. 2004, 64:5004-5012.
44. Singh S., Aggarwal B.B. Activation of transcription factor NF-k{cyrillic}B is suppressed by curcumin (diferuloylmethane). J. Biol. Chem. 1995, 270:24995-25000.
45. Sreekanth D., Arunasree M.K., Roy K.R., Reddy T.C., Reddy G.V., Reddanna P. Betanin a betacyanin pigment purified from fruits of Opuntia ficus-indica induces apoptosis in human chronic myeloid leukemia Cell line-K562. Phytomedicine 2007, 14:739-746.
46. Subhashini J., Mahipal S.V.K., Reddy M.C., Reddy M.M., Rachamallu A., Reddanna P. Molecular mechanisms in C-Phycocyanin induced apoptosis in human chronic myeloid leukemia cell line-K 562. Biochem. Pharmacol. 2004, 68:453-462.
47. Subhashini J., Mahipal S.V.K., Reddanna P. Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro. Cancer Lett. 2005, 224:31-43.
48. Tang X., Sun Y.J., Half E., Kuo M.T., Sinicrope F. Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Res. 2002, 62:4903-4908.
49. Wang M.T., Honn K.V., Nie D. Cyclooxygenases, prostanoids, and tumor progression. Cancer Metast. Rev. 2007, 26:525-534.
50. Waskewich C., Blumenthal R.D., Li H.L., Stein R., Goldenberg D.M., Burton J. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res. 2002, 62:2029-2033.
51. Wong S., Witte O.N. THE BCR-ABL sTORY: bench to bedside and back. Annu. Rev. Immunol. 2004, 22:247-306.
52. Yeh R.D., Chen J.C., Lai T.Y., Yang J.S., Yu C.S., Chiang J.H., Lu C.C., Yang S.T., Yu C.C., Chang S.J., Lin H.Y., Chung J.G. Gallic acid induces G0/G1 phase arrest and apoptosis in human leukemia HL-60 cells through inhibiting Cyclin D and E, and activating mitochondria-dependent pathway. Anticancer Res. 2011, 31(9):2821-2832.
53. Zhang G.S., Liu D.S., Dai C.W., Li R.J. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of COX-2 expression and are synergistic with hydroxyurea or imatinib. Am. J. Hematol. 2006, 81:242-245.